Moderna completed application to U.S. FDA for EUA of omicron-targeting bivalent Covid-19 booster vaccine
On Aug. 22, 2022, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of Moderna COVID-19 Vaccine to include the 2024-2025 formula.
The Moderna COVID-19 Vaccine (2024-2025 Formula) includes a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.
The Moderna COVID-19 Vaccine (2024-2025 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19.
Tags:
Source: U.S. Food and Drug Administration
Credit:
